We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
By Nishant Mohan
International stocks trading in New York closed mostly higher on Thursday.
The BNY Mellon index of American depositary receipts gained 0.74% to 144.61. The European index increased 0.53% to 134.77, the Asian index rose 0.88% to 173.44, the Latin American index rose 1.99% to 209.06 and the emerging markets index increased 1.2% to 305.11.
Shire PLC and AstraZeneca were among the companies with ADRs that traded actively.
ADRs of Summit Therapeutics PLC (SMMT) fell 6.67% to $2.38 Thursday, continuing Wednesday's reaction to the company's canceled development of its ezutromid treatment for Duchenne muscular dystrophy.
Shire (SHPG) shares gained following the failure of Takeda Pharmaceutical Co. to acquire the company. ADRs of the company grew 4.43% on Thursday to $168.41.
ADRs of Teva Pharmaceutical Industries (TEVA) gained 4.06% to $24.60 a share following the drug company's announcement of clinical trial data supporting its drug to prevent migraines.
AstraZeneca PLC (AZN) said it planned to sell licenses for its antipsychotic drugs Seroquel and Seroquel XR to Luye Pharma Group Ltd. in the U.K., China and other international markets. ADRs of the company gained 1.01% to $34.90 a share Thursday.
Write to Nishant Mohan at nishant.mohan@wsj.com
(END) Dow Jones Newswires
June 28, 2018 16:51 ET (20:51 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions